Characterization of tumor-suppressive function of SOX6 in human esophageal squamous cell carcinoma

Clinical Cancer Research

Volumn 17, Issue 1, 2011, Pages 46-55

  Qin, Yan Ru ^a   Tang, Hong ^a   Xie, Fajun ^b   Liu, Haibo ^b   Zhu, Yinghui ^b   Ai, Jiaoyu ^a   Chen, Leilei ^c   Li, Yan ^b   Kwong, Dora L ^c   Fu, Li ^b,c   Guan, Xin Yuan ^b,c  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CYCLIN A; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 1; MESSENGER RNA; PROTEIN P53; TRANSCRIPTION FACTOR SOX6;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CAUSE SPECIFIC SURVIVAL; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DOWN-REGULATION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SOXD TRANSCRIPTION FACTORS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78751496203     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1155     Document Type: Article

References (42)

1. Shimada H, Nabeya Y, Ochiai T, Matsubara H, Shiratori T, Gunji Y, et al. Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 2003;133:486-94.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57:43-66.
3. Metzger R, Schneider PM, Warnecke-Eberz U, Brabender J, Holscher AH. Molecular biology of esophageal cancer. Onkologie 2004;27:200-6.
4. He LR, Liu MZ, Li BK, Rao HL, Liao YJ, Zhang LJ, et al. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009;100:1591-6.
5. Yuen HF, Chan YP, Law S, Srivastava G, El-Tanani M, Mak TW, et al. DJ-1 could predict worse prognosis in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2008;17:3593-602.
6. Connor F, Wright E, Denny P, Koopman P, Ashworth A. The Sryrelated HMG box-containing gene Sox6 is expressed in the adult testis and developing nervous system of the mouse. Nucleic Acids Res 1995;23:3365-72.
7. Lefebvre V, Li P, de Crombrugghe B. A new long form of Sox5 (LSox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene. EMBO J 1998;17:5718-33.
8. Hamada-Kanazawa M, Ishikawa K, Ogawa D. Suppression of Sox6 in P19 cells leads to failure of neuronal differentiation by retinoic acid and induces retinoic acid-dependent apoptosis. FEBS Lett 2004;577:60-6.
9. Iguchi H, Urashima Y, Inagaki Y, Okamura M, Tanaka T, Uchida A, et al. SOX6 suppresses cyclin D1 promoter activity by interacting with beta-catenin and histone deacetylase 1, and its down-regulation induces pancreatic beta-cell proliferation. J Biol Chem 2007;282:19052-61.
10. Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cellcycle arrest and apoptosis. Br J Cancer 2008;98:824-31.
11. Aaboe M, Birkenkamp-Demtroder K, Wiuf C, Sorensen FB, Thykjaer T, Sauter G, et al. SOX4 expression in bladder carcinoma: clinical aspects and in vitro functional characterization. Cancer Res 2006;66:3434-42.
12. Afonja O, Raaka BM, Huang A, Das S, Zhao X, Helmer E, et al. RAR agonists stimulate SOX9 gene expression in breast cancer cell lines: evidence for a role in retinoid-mediated growth inhibition. Oncogene 2002;21:7850-60.
13. Drivdahl R, Haugk KH, Sprenger CC, Nelson PS, Tennant MK, Plymate SR. Suppression of growth and tumorigenicity in the prostate tumor cell line M12 by overexpression of the transcription factor SOX9. Oncogene 2004;23:4584-93.
14. Aleman A, Adrien L, Lopez-Serra L, Cordon-Cardo C, Esteller M, Belbin TJ, et al. Identification of DNA hypermethylation of SOX9 in association with bladder cancer progression using CpG microarrays. Br J Cancer 2008;98:466-73.
15. Passeron T, Valencia JC, Namiki T, Vieira WD, Passeron H, Miyamura Y, et al.Upregulation of SOX9 inhibits the growth of human and mouse melanomas and restores their sensitivity to retinoic acid. J Clin Invest 2009;119:954-63.
16. Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of 21 newly established esophageal cancer cell lines. Cancer 1992;69:277-84.
17. Xie D, Sham JS, Zeng WF, Lin HL, Che LH, Wu HX, et al. Heterogeneous expression and association of beta-catenin, p16 and c-myc in multistage colorectal tumorigenesis and progression detected by tissue microarray. Int J Cancer 2003;107:896-902.
18. Fu L, Qin YR, Xie D, Chow HY, Ngai SM, Kwong DL, et al. Identification of alpha-actinin 4 and 67 kDa laminin receptor as stage-specific markers in esophageal cancer via proteomic approaches. Cancer 2007;110:2672-81.
19. Cao ZA, Daniel D, Hanahan D. Sub-lethal radiation enhances antitumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2002;2:11.
20. Wegner M. From head to toes: the multiple facets of Sox proteins. Nucleic Acids Res 1999;27:1409-20.
21. Schepers GE, Teasdale RD, Koopman P. Twenty pairs of sox: extent, homology, and nomenclature of the mouse and human sox transcription factor gene families. Dev Cell 2002;3:167-70.
22. Chew LJ, Gallo V. The Yin and Yang of Sox proteins: activation and repression in development and disease. J Neurosci Res 2009;87:3277-87.
23. Ueda R, Yoshida K, Kawakami Y, Kawase T, Toda M. Immunohistochemical analysis of SOX6 expression in human brain tumors. Brain Tumor Pathol 2004;21:117-20.
24. Ueda R, Yoshida K, Kawakami Y, Kawase T, Toda M. Expression of a transcriptional factor, SOX6, in human gliomas. Brain Tumor Pathol 2004;21:35-8.
25. Carnero A, Hannon GJ. The INK4 family of CDK inhibitors. Curr Top Microbiol Immunol 1998;227:43-55.
26. Parry D, Mahony D, Wills K, Lees E. Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol 1999;19:1775-83.
27. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31.
28. Kohn KW. Molecular interaction map of the mammalian cell cycle control and DNA repair systems. Mol Biol Cell 1999;10:2703-34.
29. el-Deiry WS, Harper JW, O'Connor PM, Velculescu VE, Canman CE, Jackman J, et al. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 1994;54:1169-74.
30. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 1995;55:5187-90.
31. Aaltomaa S, Eskelinen M, Lipponen P. Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. Prostate 1999;38:175-82.
32. Mrena J, Wiksten JP, Kokkola A, Nordling S, Haglund C, Ristimaki A. Prognostic significance of cyclin A in gastric cancer. Int J Cancer 2006;119:1897-901.
33. Ahlin C, Zhou W, Holmqvist M, Holmberg L, Nilsson C, Jirstrom K, et al. Cyclin A is a proliferative marker with good prognostic value in node-negative breast cancer. Cancer Epidemiol Biomarkers Prev 2009;18:2501-6.
34. Huelsken J, Birchmeier W. New aspects of Wnt signaling pathways in higher vertebrates. Curr Opin Genet Dev 2001;11: 547-53.
35. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810.
36. Zhang C, Basta T, Jensen ED, Klymkowsky MW. The beta-catenin/VegT- regulated early zygotic gene Xnr5 is a direct target of SOX3 regulation. Development 2003;130:5609-24.
37. Kan L, Israsena N, Zhang Z, Holmberg L, Nilsson C, Jirstrom K, et al. Sox1 acts through multiple independent pathways to promote neurogenesis. Dev Biol 2004;269:580-94.
38. Akiyama H, Lyons JP, Mori-Akiyama Y, Yang X, Zhang R, Zhang Z, et al. Interactions between Sox9 and beta-catenin control chondrocyte differentiation. Genes Dev 2004;18:1072-87.
39. Sinner D, Kordich JJ, Spence JR, Opoka R, Rankin S, Lin SC, et al. Sox17 and Sox4 differentially regulate beta-catenin/T-Cell factor activity and proliferation of colon carcinoma cells. Mol cell Biol 2007;27:7802-15.
40. Orford K, Orford CC, Byers SW. Exogenous expression of the β-catenin regulates contact inhibition, anchorage-independent growth, anoikis and radiation-induced cell cycle arrest. J Cell Biol 1999;146:855-67
41. Polakis P. More than one way to skin a catenin. Cell 2001;105:563-6.
42. Sadot E, Geiger B, Oren M, Ben-Ze'ev A. Down-regulation of betacatenin by activated p53. Mol Cell Biol 2001;21:6768-81.